The global Recombinant DNA Technology Market is estimated to be valued at US$ 156.89 Mn or Mn in 2023 and is expected to exhibit a CAGR of 7.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Recombinant DNA technology involves the insertion of a specific gene into a vector system, such as a plasmid or virus, and into a host organism that can replicate the construct, usually a bacterium, yeast, or other type of cell culture. This technology has widespread applications in the production of therapeutic proteins, vaccines, and industrially important enzymes.

Market key trends:
Growing application of recombinant DNA technology in biotechnology and pharmaceutical industries is expected to be a major trend in the recombinant DNA technology market over the forecast period. Biotechnologists and pharmaceutical companies are increasingly using recombinant DNA technology to develop novel therapeutics such as vaccines, insulin, growth hormones, monoclonal antibodies and recombinant proteins. Moreover, gene therapy which involves correction of defective genes that cause disease using recombinant DNA technology is also gaining increased acceptance and growth. Rising demand for biologics and biosimilars globally will fuel the growth of recombinant DNA technology in drug discovery and production.
Market key trends:
Recombinant DNA technology allows for manufacturing of therapeutic proteins like insulin and growth hormones in bacterial and mammalian cells which are otherwise difficult to extract from their original sources. This technology is increasingly being used for developing new biologics and vaccines for various diseases. One of the major trends is the use of recombinant protein and DNA vaccines for infectious diseases like influenza, hepatitis B, human papilloma virus. The recombinant protein vaccines mimic the structure of disease causing organism and trigger immune response without causing the actual disease. This reduces safety concerns associated with live attenuated and inactivated vaccines.

SWOT Analysis
Strength: Recombinant DNA technology allows mass production of therapeutics with high purity and consistency. It offers scalable production of complex protein structures.
Weakness: High capital investment is required to set up facilities for rDNA therapeutics production. Strict biosafety regulations add to production costs.
Opportunity: Growing incidence of chronic diseases and various types of cancers is driving R&D of novel biologics. Developing countries offer market opportunity due to increasing healthcare expenditures.
Threats: Biosimilar competition exerts pricing pressure on biologic products. Stringent regulatory approvals and long development cycles are challenges faced by companies.

Key Takeaways
The global Recombinant DNA Technology Market Share  is expected to witness high growth, exhibiting CAGR of 7.9% over the forecast period, due to increasing prevalence of chronic diseases. North America is expected to dominate the market throughout the forecast period owing to presence of major players and high adoption of biologics for treatment in the region.

The global recombinant DNA technology market size was valued at US$ 156.89 Mn in 2023. Growing demand for biologics and targeted therapies for conditions like cancer, infectious diseases is a key factor driving market growth. Biologics have revolutionized treatment of various chronic and life-threatening illnesses. Their demand will continue to increase with expanding therapeutic applications.

Key players operating in the recombinant DNA technology market are Thermo Fisher Scientific, Inc., Biogen, Inc., Sanofi Pasteur, Merck & Co., Inc., Pfizer, Inc., Profacgen, Amgen, Inc., and Monsanto Company. Thermo Fisher, Biogen and Amgen have established manufacturing infrastructure and robust pipelines for recombinant biologics. Merck, Pfizer, Sanofi are also engaged in R&D and production of recombinant vaccines and proteins for various diseases.